Genomma Lab Internacional Stock Price To Sales
Genomma Lab Internacional fundamentals help investors to digest information that contributes to Genomma Lab's financial success or failures. It also enables traders to predict the movement of Genomma Pink Sheet. The fundamental analysis module provides a way to measure Genomma Lab's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Genomma Lab pink sheet.
Genomma |
Genomma Lab Internacional Company Price To Sales Analysis
Genomma Lab's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Genomma Lab Price To Sales | 0.05 X |
Most of Genomma Lab's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Genomma Lab Internacional is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
CompetitionBased on the latest financial disclosure, Genomma Lab Internacional has a Price To Sales of 0.0526 times. This is 99.75% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The price to sales for all United States stocks is 99.54% higher than that of the company.
Genomma Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Genomma Lab's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Genomma Lab could also be used in its relative valuation, which is a method of valuing Genomma Lab by comparing valuation metrics of similar companies.Genomma Lab is currently under evaluation in price to sales category among its peers.
Genomma Fundamentals
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0921 | |||
| Profit Margin | 0.08 % | |||
| Operating Margin | 0.20 % | |||
| Current Valuation | 1.09 B | |||
| Shares Outstanding | 1 B | |||
| Shares Owned By Insiders | 29.00 % | |||
| Shares Owned By Institutions | 29.10 % | |||
| Price To Earning | 11.09 X | |||
| Price To Book | 1.38 X | |||
| Price To Sales | 0.05 X | |||
| Revenue | 15.49 B | |||
| Gross Profit | 9.56 B | |||
| EBITDA | 2.84 B | |||
| Net Income | 1.31 B | |||
| Cash And Equivalents | 1.3 B | |||
| Cash Per Share | 1.30 X | |||
| Total Debt | 3.83 B | |||
| Debt To Equity | 0.51 % | |||
| Current Ratio | 1.67 X | |||
| Book Value Per Share | 10.98 X | |||
| Cash Flow From Operations | 1.47 B | |||
| Earnings Per Share | 0.07 X | |||
| Number Of Employees | 2.3 K | |||
| Beta | 0.53 | |||
| Market Capitalization | 973.77 M | |||
| Total Asset | 21.54 B | |||
| Annual Yield | 0.05 % | |||
| Net Asset | 21.54 B | |||
| Last Dividend Paid | 0.38 |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in Genomma Pink Sheet
If you are still planning to invest in Genomma Lab Internacional check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Genomma Lab's history and understand the potential risks before investing.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Stocks Directory Find actively traded stocks across global markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |